Skip to main content
Clinical Trials/NCT02528097
NCT02528097
Terminated
Not Applicable

A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis

NYU Langone Health1 site in 1 country2 target enrollmentSeptember 2010

Overview

Phase
Not Applicable
Intervention
Standard Care
Conditions
Spontaneous Bacterial Peritonitis
Sponsor
NYU Langone Health
Enrollment
2
Locations
1
Primary Endpoint
Renal Failure
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

Spontaneous bacterial peritonitis (SBP) is a common and frequently fatal complication of end-stage liver disease with a mortality of up to 10% primarily due to the development of kidney failure. Current standard practice is to treat this infection with broad spectrum antibiotics and salt-poor albumin administration on day one and three of treatment. In this study the investigators test the hypothesis that the administration of a second dose of albumin at 48 hours only to patients with renal insufficiency is as effective at preventing kidney failure as administering the second dose to all patients at 72 hours. In addition, a kidney function determined approach to albumin dosing may lead to substantial cost and resource saving from decreased albumin use without compromising treatment efficacy.

Registry
clinicaltrials.gov
Start Date
September 2010
End Date
January 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18 to 75
  • Evidence of end stage liver disease / cirrhosis
  • Documented SBP (ANC \> 250 or positive ascites culture
  • Ability to provide informed consent
  • Serum Creatinine \> 1.0 mg/dL and/or Total Bilirubin \> 4.0 mg/dL

Exclusion Criteria

  • Nonportal hypertensive ascites (i.e. malignancy)

Arms & Interventions

Active Comparator Standard Care

albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)

Intervention: Standard Care

Experimental

Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr \> 1.0 or BUN or Cr are above baseline.

Intervention: Experimental

Outcomes

Primary Outcomes

Renal Failure

Time Frame: At any point from time 0 through day 3

Primary outcome is the presence of renal failure at any point from the start of the study (time 0) through 72 hours

Secondary Outcomes

  • All Cause Mortality(At any point from time 0 through day 3)

Study Sites (1)

Loading locations...

Similar Trials